Access to Chimeric Antigen Receptor T-Cell Therapy in Patients With Diffuse Large B-Cell Lymphoma
This case-control study evaluates the delay in treating relapsed or refractory diffuse large B-cell lymphoma due to distant access to chimeric antigen receptor T-cell (CAR T) therapy.
Authors
- Constance Lau
- Hil Hsu (ORCID: https://orcid.org/0000-0003-4608-4935)
- Miguel‐Angel Perales (ORCID: https://orcid.org/0000-0002-5910-4571)
- Anik R. Patel (ORCID: https://orcid.org/0000-0001-9091-8904)
- Anirban Basu
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Bellevue College (US)
- Cornell University (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Kite (United States) (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.38602
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences
- National Institutes of Health
- Kite Pharma
- National Cancer Institute